» Articles » PMID: 18842730

Initial B-cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia

Abstract

A window of opportunity for immune responses to extinguish human immunodeficiency virus type 1 (HIV-1) exists from the moment of transmission through establishment of the latent pool of HIV-1-infected cells. A critical time to study the initial immune responses to the transmitted/founder virus is the eclipse phase of HIV-1 infection (time from transmission to the first appearance of plasma virus), but, to date, this period has been logistically difficult to analyze. To probe B-cell responses immediately following HIV-1 transmission, we have determined envelope-specific antibody responses to autologous and consensus Envs in plasma donors from the United States for whom frequent plasma samples were available at time points immediately before, during, and after HIV-1 plasma viral load (VL) ramp-up in acute infection, and we have modeled the antibody effect on the kinetics of plasma viremia. The first detectable B-cell response was in the form of immune complexes 8 days after plasma virus detection, whereas the first free plasma anti-HIV-1 antibody was to gp41 and appeared 13 days after the appearance of plasma virus. In contrast, envelope gp120-specific antibodies were delayed an additional 14 days. Mathematical modeling of the earliest viral dynamics was performed to determine the impact of antibody on HIV replication in vivo as assessed by plasma VL. Including the initial anti-gp41 immunoglobulin G (IgG), IgM, or both responses in the model did not significantly impact the early dynamics of plasma VL. These results demonstrate that the first IgM and IgG antibodies induced by transmitted HIV-1 are capable of binding virions but have little impact on acute-phase viremia at the timing and magnitude that they occur in natural infection.

Citing Articles

SIV-specific neutralizing antibody induction following selection of a PI3K drive-attenuated variant.

Yamamoto H, Matano T Elife. 2025; 12.

PMID: 40029304 PMC: 11875539. DOI: 10.7554/eLife.88849.


A Pentavalent HIV-1 Subtype C Vaccine Containing Computationally Selected gp120 Strains Improves the Breadth of V1V2 Region Responses.

Shen X, Korber B, Spreng R, Sawant S, deCamp A, McMillan A Vaccines (Basel). 2025; 13(2).

PMID: 40006680 PMC: 11860947. DOI: 10.3390/vaccines13020133.


Efficient epistasis inference via higher-order covariance matrix factorization.

Shimagaki K, Barton J bioRxiv. 2024; .

PMID: 39464126 PMC: 11507688. DOI: 10.1101/2024.10.14.618287.


Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response.

Rahman M, Bissa M, Scinto H, Howe S, Sarkis S, Ma Z Nat Commun. 2024; 15(1):9102.

PMID: 39438480 PMC: 11496677. DOI: 10.1038/s41467-024-53359-2.


Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

Naicker V, Laher F, Bekker L, Seaton K, Allen M, De Rosa S PLOS Glob Public Health. 2024; 4(9):e0003319.

PMID: 39302924 PMC: 11414935. DOI: 10.1371/journal.pgph.0003319.


References
1.
Stafford M, Corey L, Cao Y, Daar E, Ho D, Perelson A . Modeling plasma virus concentration during primary HIV infection. J Theor Biol. 2000; 203(3):285-301. DOI: 10.1006/jtbi.2000.1076. View

2.
Xu W, Hofmann-Lehmann R, McClure H, Ruprecht R . Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine. 2002; 20(15):1956-60. DOI: 10.1016/s0264-410x(02)00077-4. View

3.
Dianzani F, Antonelli G, Riva E, Turriziani O, Antonelli L, Tyring S . Is human immunodeficiency virus RNA load composed of neutralized immune complexes?. J Infect Dis. 2002; 185(8):1051-4. DOI: 10.1086/340043. View

4.
Gasper-Smith N, Crossman D, Whitesides J, Mensali N, Ottinger J, Plonk S . Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J Virol. 2008; 82(15):7700-10. PMC: 2493338. DOI: 10.1128/JVI.00605-08. View

5.
Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, Aubertin A . Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol. 2006; 80(12):6177-81. PMC: 1472578. DOI: 10.1128/JVI.02625-05. View